Welcome to our dedicated page for Sensei Biotherapeutics SEC filings (Ticker: SNSE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sensei Biotherapeutics, Inc. filings document a Nasdaq-listed clinical-stage oncology company, its common stock, and its disclosure obligations around pipeline development, operating results, governance, and capital structure. Material-event reports cover financial results, Regulation FD disclosures, board composition and compensation arrangements, and the completed acquisition of Faeth Therapeutics, including acquired-business financial statements and pro forma combined financial information.
Proxy and governance filings describe shareholder voting matters, director and board matters, equity compensation, preferred stock conversion-related disclosures, authorized-share matters, material agreements, and other capital-structure topics. The filing record also reflects clinical and regulatory disclosure categories for PIKTOR and solnerstotug within the company’s oncology development business.
SNSE submitted a Form 144 notice reporting a proposed Rule 144 sale of 3,374 common shares to be effected on 02/24/2026 pursuant to an option granted on 02/15/2023. The filing also discloses prior sales of 42,594 common shares on 02/19/2026 for $1,094,370.79.
Sensei Biotherapeutics, Inc. reported that Chief Operating Officer Anand Kiran Parikh acquired several equity awards in connection with the Faeth transaction and new compensation grants. On February 19, 2026, he received 1,239,305 employee stock options with a stated price of $0.00 per share. On February 17, 2026, he acquired 809,822 shares of Series B Non-Voting Convertible Preferred Stock and additional employee stock options covering 92,533 and 56,673 shares, all recorded as awards at $0.00 per share.
Footnotes explain that each share of Series B Preferred Stock is convertible into 1,000 shares of common stock with no expiration date and was received in exchange for 4,062,777 shares of Faeth Holdings Therapeutics, Inc. common stock under a Merger Agreement among Sensei, two Sapphire Merger Subs, HoldCo and Faeth. Other footnotes state that certain options were received in exchange for Faeth stock options with a $0.23 exercise price, with one such option vesting in 48 equal monthly installments beginning August 1, 2022. A separate option grant is immediately exercisable, while another vests 25% on February 19, 2027 and the remainder in 36 equal monthly installments thereafter.
Sensei Biotherapeutics, Inc. filed an initial insider ownership report for Parikh Anand Kiran. The filing identifies him as both a director and the Chief Operating Officer of the company. This Form 3 does not report any specific stock transactions or share amounts.
James Peyer filed a Form 144 reporting a proposed sale of 950 common shares on 02/18/2026. The filing lists the sale as an option granted 06/11/2024 and names Fidelity Brokerage Services LLC as the broker. The excerpt also shows prior sales of 841 common shares on 12/09/2025 for $6,706.72.
Sensei Biotherapeutics is transforming its business by acquiring Faeth Therapeutics and raising about $200 million in a concurrent private placement of Series B non-voting convertible preferred stock. These preferred shares are each convertible into 1,000 common shares if stockholders later approve the needed proposals.
After the merger and financing, former Faeth holders and new investors will own the vast majority of Sensei, while existing stockholders drop to about 4.9% of the fully diluted common stock. The deal makes Faeth’s lead cancer drug PIKTOR Sensei’s main program, with funding aimed at Phase 2 endometrial cancer data and a Phase 1b breast cancer trial by year-end 2026.
Donenberg Phillip B. reported acquisition or exercise transactions in a Form 4 filing for SNSE. The filing lists transactions totaling 1,900 shares. Following the reported transactions, holdings were 1,900 shares.
Sensei Biotherapeutics, Inc. director Phillip B. Donenberg filed an initial Form 3 reporting his beneficial ownership of the company’s securities as of February 13, 2026. The filing states that no securities are beneficially owned and lists no derivative positions or transactions.
Sensei Biotherapeutics, Inc. expanded its board of directors from three to five members and appointed Christopher W. Gerry and Phillip B. Donenberg as new directors, effective immediately. Gerry is the Company’s President, Principal Executive Officer and General Counsel, with prior legal and biotech experience. Donenberg brings extensive financial leadership and public company board experience in gene therapy and therapeutics. Donenberg will receive compensation under Sensei’s standard non-employee director program, and both new directors will enter into the Company’s standard form of indemnification agreement.
Sensei Biotherapeutics security holder plans a small stock sale under Rule 144. The notice covers the proposed sale of 1,169 shares of common stock through Fidelity Brokerage Services LLC on NASDAQ, with an aggregate market value of 11,485.83.
The shares were acquired through restricted stock vesting from the issuer on several dates between 03/09/2023 and 03/09/2025 as compensation. The person filing represents that they are not aware of any material adverse, nonpublic information about the company’s current or prospective operations.
Sensei Biotherapeutics, Inc. (SNSE) reported the initial shareholdings of its President and Principal Executive Officer as of 11/14/2025. The executive directly beneficially owns 1,574 shares of common stock, primarily in the form of restricted stock units, with 1,444 shares already vested and 130 shares scheduled to vest in two equal installments on February 15, 2026 and February 15, 2027, subject to continued service.
The executive also holds multiple stock options to purchase common stock with different exercise prices and vesting schedules. These options cover separate grants that generally vest monthly over thirty-six months from their respective commencement dates, with one grant vesting 100% on December 1, 2025, all conditioned on continued service with Sensei Biotherapeutics.